In addition to somatic loss-of-function mutations that foster thyroid cancers, there is a high incidence of de novo inactivating TRα and TRβ mutations in hepatocellular, renal, and thyroid cancers [107] which may relate to selection pressures during tumor progression [111]. This evidence concerns the gene THRB and neoplasm.